BL
Therapeutic Areas
Zhimeng Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ZM-H1505R | Chronic Hepatitis B | Phase 1 |
| Undisclosed CAM | Chronic Hepatitis B | Clinical |
| Undisclosed Immunomodulator | Chronic Hepatitis B | Clinical |
| Undisclosed Program | Refractory Epilepsy | Clinical |
Leadership Team at Zhimeng Biopharma
HC
Huanming Chen, Ph.D.
President and CEO
ZZ
Zhijun Zhang, Ph.D.
Leadership Team
JJ
Jessie Jiang, Ph.D.
Senior Medical Director
RG
Ruoling Guo, Ph.D.
Senior Director, Global Clinical Operations
GL
Gang Liu, Ph.D.
Director, Chemistry, Manufacturing and Controls (CMC)